1028 related articles for article (PubMed ID: 28464441)
1. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
Front Immunol; 2021; 12():705096. PubMed ID: 34434192
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for recurrent/metastatic head and neck cancer.
Alfieri S; Cavalieri S; Licitra L
Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):152-156. PubMed ID: 29432222
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
9. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
10. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
Busch CJ; Laban S; Knecht R; Hoffmann TK
HNO; 2016 Oct; 64(10):708-16. PubMed ID: 27604282
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
Outh-Gauer S; Alt M; Le Tourneau C; Augustin J; Broudin C; Gasne C; Denize T; Mirghani H; Fabre E; Ménard M; Scotte F; Tartour E; Badoual C
Cancer Treat Rev; 2018 Apr; 65():54-64. PubMed ID: 29547766
[TBL] [Abstract][Full Text] [Related]
14. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
[TBL] [Abstract][Full Text] [Related]
16. Novel Treatment Options in Head and Neck Cancer.
Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Economopoulou P; Kotsantis I; Psyrri A
Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
[TBL] [Abstract][Full Text] [Related]
18. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
19. Immunotherapy in head and neck cancer: evidence and perspectives.
Tosoni A; Franceschi E; Pasquini E; Lanese A; Donini E; Foschini MP; Dall'Olio D; Brandes AA
Immunotherapy; 2017 Dec; 9(16):1351-1358. PubMed ID: 29185392
[TBL] [Abstract][Full Text] [Related]
20. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Solomon B; Young RJ; Rischin D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
